The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee-Reference-Cited by-全球学者库

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

Published:2022-09-15 Issue:11 Volume:140 Page:1229-1253
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Campo Elias¹^ORCID,Jaffe Elaine S.²^ORCID,Cook James R.³^ORCID,Quintanilla-Martinez Leticia⁴^ORCID,Swerdlow Steven H.⁵,Anderson Kenneth C.⁶,Brousset Pierre⁷^ORCID,Cerroni Lorenzo⁸,de Leval Laurence⁹,Dirnhofer Stefan¹⁰,Dogan Ahmet¹¹^ORCID,Feldman Andrew L.¹²^ORCID,Fend Falko⁴,Friedberg Jonathan W.¹³,Gaulard Philippe¹⁴¹⁵,Ghia Paolo¹⁶^ORCID,Horwitz Steven M.¹⁷,King Rebecca L.¹²,Salles Gilles¹⁷^ORCID,San-Miguel Jesus¹⁸^ORCID,Seymour John F.¹⁹^ORCID,Treon Steven P.⁶^ORCID,Vose Julie M.²⁰^ORCID,Zucca Emanuele²¹^ORCID,Advani Ranjana²²,Ansell Stephen²³,Au Wing-Yan²⁴,Barrionuevo Carlos²⁵^ORCID,Bergsagel Leif²⁶^ORCID,Chan Wing C.²⁷,Cohen Jeffrey I.²⁸,d’Amore Francesco²⁹,Davies Andrew³⁰^ORCID,Falini Brunangelo³¹^ORCID,Ghobrial Irene M.⁶³²^ORCID,Goodlad John R.³³^ORCID,Gribben John G.³⁴^ORCID,Hsi Eric D.³⁵^ORCID,Kahl Brad S.³⁶^ORCID,Kim Won-Seog³⁷,Kumar Shaji²³^ORCID,LaCasce Ann S.⁶^ORCID,Laurent Camille⁷,Lenz Georg³⁸,Leonard John P.³⁹,Link Michael P.⁴⁰,Lopez-Guillermo Armando⁴¹,Mateos Maria Victoria⁴²^ORCID,Macintyre Elizabeth⁴³^ORCID,Melnick Ari M.⁴⁴^ORCID,Morschhauser Franck⁴⁵^ORCID,Nakamura Shigeo⁴⁶,Narbaitz Marina⁴⁷,Pavlovsky Astrid⁴⁸,Pileri Stefano A.⁴⁹^ORCID,Piris Miguel⁵⁰^ORCID,Pro Barbara⁵¹,Rajkumar Vincent¹²,Rosen Steven T.⁵²,Sander Birgitta⁵³,Sehn Laurie⁵⁴,Shipp Margaret A.⁶^ORCID,Smith Sonali M.⁵⁵^ORCID,Staudt Louis M.⁵⁶,Thieblemont Catherine⁵⁷⁵⁸,Tousseyn Thomas⁵⁹,Wilson Wyndham H.⁵⁶,Yoshino Tadashi⁶⁰,Zinzani Pier-Luigi⁶¹^ORCID,Dreyling Martin⁶²^ORCID,Scott David W.⁵⁴^ORCID,Winter Jane N.⁶³,Zelenetz Andrew D.¹⁷⁶⁴^ORCID

Affiliation:

1. 1Haematopathology Section, Hospital Clínic of Barcelona, Institut d’Investigaciones Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Centro de Investigación Biomédica en Red de Cancer (CIBERONC), Barcelona, Spain;

2. 2Hematopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD;

3. 3Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH;

4. 4Institute of Pathology and Neuropathology, Eberhard Karls University of Tübingen and Comprehensive Cancer Center, University Hospital Tübingen, Tübingen, Germany;

5. 5Department of Pathology, University of Pittsburgh School of Medicine, University of Pittsburgh, Pittsburgh, PA;

6. 6Dana-Farber Cancer Institute, Boston, MA;

7. 7Department of Pathology, Institut Universitaire du Cancer de Toulouse-Oncopole, and Laboratoire d’Excellence Toulouse Cancer, Toulouse, France;

8. 8Department of Dermatology, Medical University of Graz, Graz, Austria;

9. 9Institute of Pathology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and Lausanne University, Lausanne, Switzerland;

10. 10Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland;

11. 11Laboratory of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY;

12. 12Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN;

13. 13Wilmot Cancer Institute, University of Rochester, Rochester, NY;

14. 14Department of Pathology, University Hospital Henri Mondor, Assistance Publique-Hôpitaux de Paris (AP-HP), Créteil, France;

15. 15Mondor Institute for Biomedical Research, INSERM U955, Faculty of Medicine, University of Paris-Est Créteil, Créteil, France;

16. 16Strategic Research Program on Chronic Lymphocytic Leukemia, Division of Experimental Oncology, IRCCS Ospedale San Raffaele and Università Vita-Salute San Raffaele, Milan, Italy;

17. 17Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;

18. 18Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, CIBERONC, Pamplona, Spain;

19. 19Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia;

20. 20Division of Hematology-Oncology, Department of Internal Medicine, University of Nebraska Medical Center, University of Nebraska, Omaha, NE;

21. 21Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, and Institute of Oncology Research, Università della Svizzera Italiana, Bellinzona, Switzerland;

22. 22Stanford Cancer Center, Blood and Marrow Transplant Program, Stanford University, Stanford, CA;

23. 23Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN;

24. 24Blood-Med Clinic, Hong Kong, People’s Republic of China;

25. 25Department of Pathology, Instituto Nacional de Enfermedades Neoplásicas, Faculty of Medicine, Universidad Nacional Mayor de San Marcos, Lima, Peru;

26. 26Division of Hematology, Department of Internal Medicine, Mayo Clinic, Phoenix, AZ;

27. 27Department of Pathology, City of Hope National Medical Center, Duarte, CA;

28. 28Medical Virology Section, Laboratory of Infectious Diseases, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Bethesda, MD;

29. 29Department of Hematology, Aarhus University Hospital, Aarhus, Denmark;

30. 30Cancer Research UK Centre, Centre for Cancer Immunology, Faculty of Medicine, Southampton General Hospital, University of Southampton, Southampton, United Kingdom;

31. 31Institute of Hematology and Center for Hemato-Oncology Research, Hospital of Perugia, University of Perugia , Perugia, Italy;

32. 32Harvard Medical School, Harvard University, Boston, MA;

33. 33National Health Service Greater Glasgow and Clyde, Glasgow, United Kingdom;

34. 34Department of Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom;

35. 35Department of Pathology, Wake Forest School of Medicine, Wake Forest University, Winston-Salem, NC;

36. 36Oncology Division, Washington University School of Medicine, Washington University in St. Louis, St. Louis, MO;

37. 37Hematology and Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea;

38. 38Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Muenster, Muenster, Germany;

39. 39Weill Department of Medicine, Weill Medical College, Cornell University, New York, NY;

40. 40Department of Pediatrics, Division of Pediatric Hematology-Oncology, Stanford University School of Medicine, Stanford University, Stanford, CA;

41. 41Department of Hematology, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain;

42. 42Department of Hematology, Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Centro de Investigación del Cancer, Universidad de Salamanca, Salamanca, Spain;

43. 43Laboratoire d’Onco-Hématologie, AP-HP, Hôpital Necker-Enfants Malades, Université de Paris Cité and Institut Necker-Enfants Malades, Paris, France;

44. 44Division of Hematology and Oncology, Weill Medical College, Cornell University, New York, NY;

45. 45Department of Hematology, Centre Hospitalier Universitaire de Lille, University Lille, Lille, France;

46. 46Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan;

47. 47Department of Pathology, Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina and Fundacion para combatir la leucemia (FUNDALEU), Buenos Aires, Argentina;

48. 48Fundación para Combatir la Leucemia (FUNDALEU), Centro de Hematología Pavlovsky, Buenos Aires, Argentina;

49. 49Haematopathology Division, IRCCS, Istituto Europeo di Oncologia, Milan, Italy;

50. 50Jiménez Díaz Foundation University Hospital, Universidad Autónoma de Madrid, Madrid, Spain;

51. 51Division of Hematology and Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL;

52. 52Beckman Research Institute, and Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA;

53. 53Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden;

54. 54Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada;

55. 55Section of Hematology/Oncology, University of Chicago, Chicago, IL;

56. 56Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD;

57. 57Service Hémato-Oncologie, AP-HP, Hôpital Saint-Louis, Paris, France;

58. 58DMU-DHI, Université de Paris-Paris Diderot, Paris, France;

59. 59Department of Pathology, Universitair Ziekenhuis Leuven Hospitals, Leuven, Belgium;

60. 60Department of Pathology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University, Okayama, Japan;

61. 61Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seragnoli", Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy;

62. 62Department of Medicine III, Ludwig-Maximilians-University Hospital, Munich, Germany;

63. 63Feinberg School of Medicine, Northwestern University, Chicago, IL; and

64. 64Weill Medical College, Cornell University, New York, NY

Abstract

AbstractSince the publication of the Revised European-American Classification of Lymphoid Neoplasms in 1994, subsequent updates of the classification of lymphoid neoplasms have been generated through iterative international efforts to achieve broad consensus among hematopathologists, geneticists, molecular scientists, and clinicians. Significant progress has recently been made in the characterization of malignancies of the immune system, with many new insights provided by genomic studies. They have led to this proposal. We have followed the same process that was successfully used for the third and fourth editions of the World Health Organization Classification of Hematologic Neoplasms. The definition, recommended studies, and criteria for the diagnosis of many entities have been extensively refined. Some categories considered provisional have now been upgraded to definite entities. Terminology for some diseases has been revised to adapt nomenclature to the current knowledge of their biology, but these modifications have been restricted to well-justified situations. Major findings from recent genomic studies have impacted the conceptual framework and diagnostic criteria for many disease entities. These changes will have an impact on optimal clinical management. The conclusions of this work are summarized in this report as the proposed International Consensus Classification of mature lymphoid, histiocytic, and dendritic cell tumors.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

https://ashpublications.org/blood/article-pdf/140/11/1229/1921035/bloodbld2022015851c.pdf

Reference319 articles.

1. A revised European-American Classification of Lymphoid Neoplasms: a proposal from the International Lymphoma Study Group;Harris;Blood.,1994

2. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project;Blood.,1997

3. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications;Campo;Blood.,2011

4. The 2016 revision of the World Health Organization Classification of Lymphoid Neoplasms;Swerdlow;Blood.,2016

Cited by 470 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SOX11+ Large B-Cell Neoplasms: Cyclin D1-Negative Blastoid/Pleomorphic Mantle Cell Lymphoma or Large B-cell Lymphoma?;Modern Pathology;2024-02

2. SOHO State-of-the-Art Updates and Next Questions: Treatment for Newly Diagnosed Peripheral T-Cell Lymphomas;Clinical Lymphoma Myeloma and Leukemia;2024-02

3. Lymphoid blood cancers, incidence and survival 2005-2023: A report from the UK’s Haematological Malignancy Research Network;Cancer Epidemiology;2024-02

4. EBV-positive Nodal T-Cell and NK-Cell Lymphoma;American Journal of Surgical Pathology;2024-01-30

5. SRRM2 may be a potential biomarker and immunotherapy target for multiple myeloma: a real-world study based on flow cytometry detection;Clinical and Experimental Medicine;2024-01-30